CELC Latest Headlines

Cantor Fitzgerald Sticks to Their Buy Rating for Celcuity (CELC)

at www.tipranks.com (Fri, 6-Nov 9:46 AM)

Celcuity Non-GAAP EPS of -$1.21 beats by $0.32

at seekingalpha.com (Thu, 5-Nov 5:40 PM)

Here are the major earnings after the close Thursday

at seekingalpha.com (Thu, 5-Nov 10:00 AM)

CELC Launches REVTORPYK in the U.S. for HR+/HER2- Advanced Breast Cancer Without PIK3CA Mutation

Market Chameleon (Wed, 30-Sep 9:41 AM)

Celcuity says REVTORPYK is now commercially available in the U.S., expanding access after July FDA approval

Market Chameleon (Wed, 30-Sep 9:19 AM)